Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Dallob A, et al. Among authors: detora l. J Clin Pharmacol. 2003 Jun;43(6):573-85. J Clin Pharmacol. 2003. PMID: 12817520 Clinical Trial.
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ; Protocol 007 Study Group. Gottesdiener K, et al. Among authors: detora l. Rheumatology (Oxford). 2002 Sep;41(9):1052-61. doi: 10.1093/rheumatology/41.9.1052. Rheumatology (Oxford). 2002. PMID: 12209041 Clinical Trial.
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, Daniels B. Saag K, et al. Among authors: detora l. Arch Fam Med. 2000 Nov-Dec;9(10):1124-34. doi: 10.1001/archfami.9.10.1124. Arch Fam Med. 2000. PMID: 11115219 Clinical Trial.
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng Q, Bolognese J, Ehrich E; Phase III Rofecoxib Geriatric Study Group. Truitt KE, et al. Among authors: detora l. Aging (Milano). 2001 Apr;13(2):112-21. doi: 10.1007/BF03351533. Aging (Milano). 2001. PMID: 11405384 Clinical Trial.
Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.
Myllykangas-Luosujärvi R, Lu HS, Chen SL, Choon D, Amante C, Chow CT, Pasero G, Genti G, Sarembock B, Zerbini CA, Vrijens F, Moan A, Rodgers DB, De Tora L, Laurenzi M; Naproxen 901 OF study group Naproxen 901 OC study group. Myllykangas-Luosujärvi R, et al. Scand J Rheumatol. 2002;31(6):337-44. doi: 10.1080/030097402320817059. Scand J Rheumatol. 2002. PMID: 12492248 Clinical Trial.
37 results